Trial Outcomes & Findings for Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer (NCT NCT00791336)

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

1 participants

Primary outcome timeframe

30 days

Results posted on

2017-07-28

Participant Flow

Participant milestones

Participant milestones
Measure	Nelfinavir Nelfinavir: 1250 mg twice daily starting for approximately 6.5 weeks.
Overall Study STARTED	1
Overall Study COMPLETED	1
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Nelfinavir n=1 Participants Nelfinavir: 1250 mg twice daily starting for approximately 6.5 weeks.
Age, Categorical <=18 years	0 Participants n=93 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=93 Participants
Age, Categorical >=65 years	0 Participants n=93 Participants
Sex: Female, Male Female	1 Participants n=93 Participants
Sex: Female, Male Male	0 Participants n=93 Participants
Region of Enrollment United States	1 participants n=93 Participants

PRIMARY outcome

Timeframe: 30 days

Population: Only 1 subject was enrolled and treated. Study was terminated due to poor enrollment. Data were not collected or analyzed due to study termination and low enrollment count (n=1).

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: long-term

Population: Only 1 subject was enrolled and treated. Study was terminated due to poor enrollment. Data were not collected or analyzed due to study termination and low enrollment count (n=1).

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 7 weeks

Population: Only 1 subject was enrolled and treated. Study was terminated due to poor enrollment. Data were not collected or analyzed due to study termination and low enrollment count (n=1).

Outcome measures

Outcome data not reported

Adverse Events

Nelfinavir

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

John M. Buatti, M.D., Chair, Department of Radiation Oncology

The University of Iowa

Phone: 319-356-2699

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place